review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Adi Aran | |
Dalit Cayam-Rand | |||
P2860 | cites work | Parent-mediated early intervention for young children with autism spectrum disorders (ASD) | Q24197951 |
Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD) | Q24198226 | ||
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects | Q24606148 | ||
Toward an exportable parent training program for disruptive behaviors in autism spectrum disorder | Q24613892 | ||
The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users | Q26768135 | ||
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders | Q26823267 | ||
Adverse health effects of marijuana use | Q26861513 | ||
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage | Q27336497 | ||
Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
Placebo-like response in absence of treatment in children with Autism | Q33453967 | ||
Prevalence and risk factors of maladaptive behaviour in young children with Autistic Disorder | Q33728345 | ||
Epilepsy and epileptiform EEG: association with autism and language disorders | Q33927352 | ||
Risperidone in children with autism and serious behavioral problems | Q33960551 | ||
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis | Q34005713 | ||
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. | Q34141036 | ||
The pleasures of play: pharmacological insights into social reward mechanisms | Q34159109 | ||
An update on pharmacotherapy for autism spectrum disorder in children and adolescents | Q34458799 | ||
A systematic review of the antipsychotic properties of cannabidiol in humans | Q34462024 | ||
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 | ||
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders | Q34557613 | ||
Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer | Q89235610 | ||
Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling | Q89397679 | ||
Prevalence and Treatment Patterns of Autism Spectrum Disorder in the United States, 2016 | Q90214039 | ||
Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors | Q90321300 | ||
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors | Q90412271 | ||
Consequences of Perinatal Cannabis Exposure | Q90660691 | ||
Cannabidiol Administration Prevents Hypoxia-Ischemia-Induced Hypomyelination in Newborn Rats | Q90704777 | ||
Cannabinoid Exposure via Lactation in Rats Disrupts Perinatal Programming of the Gamma-Aminobutyric Acid Trajectory and Select Early-Life Behaviors | Q90948570 | ||
Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System | Q90954364 | ||
Preclinical safety and efficacy of cannabidivarin for early life seizures | Q91003343 | ||
Adolescent neurodevelopment and substance use: Receptor expression and behavioral consequences | Q91210455 | ||
Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis | Q91297514 | ||
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use | Q91316496 | ||
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results | Q91513025 | ||
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder | Q91539357 | ||
Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders | Q91822788 | ||
Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration | Q91862499 | ||
Terpenoids and Phytocannabinoids Co-Produced in Cannabis Sativa Strains Show Specific Interaction for Cell Cytotoxic Activity | Q92783084 | ||
The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders | Q93082735 | ||
Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice | Q34608846 | ||
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? | Q34676610 | ||
Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being | Q34773070 | ||
Problem behavior interventions for young children with autism: a research synthesis | Q35015484 | ||
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial | Q35125984 | ||
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users | Q35431094 | ||
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report | Q35962896 | ||
Prevalence and Predictors of Complementary and Alternative Medicine Use in a Large Insured Sample of Children with Autism Spectrum Disorders | Q36036144 | ||
Estimation of the burden of active and life-time epilepsy: a meta-analytic approach | Q36135562 | ||
Endocannabinoid signaling mediates oxytocin-driven social reward | Q36300201 | ||
Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. | Q36395277 | ||
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity | Q36546326 | ||
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. | Q37030178 | ||
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans | Q37132683 | ||
The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials | Q37139119 | ||
Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence | Q37360523 | ||
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems | Q37616011 | ||
Frontotemporal dementia: what can the behavioral variant teach us about human brain organization? | Q37889021 | ||
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study | Q38191299 | ||
Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. | Q38396854 | ||
Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial | Q38412773 | ||
The relationship between cannabidiol and psychosis: A review | Q38467153 | ||
Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders | Q38586358 | ||
Atypical antipsychotics for disruptive behaviour disorders in children and youths | Q38632745 | ||
Psychopharmacological interventions in autism spectrum disorder | Q38739577 | ||
Cannabinoids: Medical implications | Q38749077 | ||
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure | Q38755199 | ||
Cannabis and epilepsy: An ancient treatment returns to the fore | Q39042588 | ||
Autism, epilepsy, and synaptopathies: a not rare association | Q39271726 | ||
Psychopathology in children and adolescents with autism compared to young people with intellectual disability | Q39764963 | ||
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
Systems analysis of stress and positive perceptions in mothers and fathers of pre-school children with autism | Q40386986 | ||
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity | Q41012471 | ||
Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe | Q41099553 | ||
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. | Q41660878 | ||
Hashish. I. The structure of cannabidiol | Q42239859 | ||
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
Medical Cannabinoids in Children and Adolescents: A Systematic Review | Q42698526 | ||
Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders | Q43628480 | ||
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability | Q44208964 | ||
High rates of psychiatric co-morbidity in individuals with Asperger's disorder | Q44517327 | ||
The Effect of Marijuana on Small Group Process | Q44869661 | ||
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders | Q45113253 | ||
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. | Q45927862 | ||
Treating a novel plasticity defect rescues episodic memory in Fragile X model mice | Q46229249 | ||
Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months | Q46580886 | ||
Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study | Q47245856 | ||
Emotional and behavioural problems in children with autism spectrum disorder | Q47290593 | ||
Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism | Q48592285 | ||
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being | Q48821406 | ||
Aggression in children and adolescents with ASD: prevalence and risk factors. | Q50301804 | ||
Risperidone and adaptive behavior in children with autism. | Q50304198 | ||
The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. | Q50304778 | ||
Patterns of emotional and behavioural disturbance associated with autistic traits in young people with severe intellectual disabilities and challenging behaviours. | Q50305438 | ||
The impact of parenting stress: a meta-analysis of studies comparing the experience of parenting stress in parents of children with and without autism spectrum disorder. | Q50306135 | ||
Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. | Q50307500 | ||
Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. | Q50312473 | ||
Determinants of stress in parents of children with autism spectrum disorders. | Q50345033 | ||
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | Q50890840 | ||
Marijuana and hostility in a small-group setting. | Q51291199 | ||
Marijuana Intoxication : Common Experiences | Q51329739 | ||
Plasma anandamide concentrations are lower in children with autism spectrum disorder. | Q52643582 | ||
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. | Q52750107 | ||
Effective treatment of spasticity using dronabinol in pediatric palliative care. | Q52981828 | ||
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study | Q58088545 | ||
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis | Q58613951 | ||
Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3 Mouse Model of Autism | Q58801901 | ||
Cannabis consumption and psychosis or schizophrenia development | Q60632683 | ||
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy | Q60907594 | ||
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55 | Q60916595 | ||
Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities | Q61449918 | ||
The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain | Q61449942 | ||
Lower circulating endocannabinoid levels in children with autism spectrum disorder | Q61806317 | ||
Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results | Q62868096 | ||
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
The entourage effect of the phytocannabinoids | Q86893365 | ||
Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders | Q88689235 | ||
P433 | issue | 1 | |
P577 | publication date | 2020-01-30 | |
P1433 | published in | Rambam Maimonides Medical Journal | Q18209815 |
P1476 | title | Medical Cannabis in Children | |
P478 | volume | 11 |
Search more.